AVN-211
AVN-211
AVN-211 (pronounced A-V-N-two-eleven) is a novel small molecule and potent 5-HT6 receptor antagonist with potential antipsychotic activity. AVN-211 is being developed by Avineuro Pharmaceuticals for the treatment of schizophrenia and other related disorders.
Etymology
The term AVN-211 is derived from the name of the company that developed it, Avineuro Pharmaceuticals. The number 211 does not have a known specific significance and is likely a part of a series of compounds developed by the company.
Pharmacology
AVN-211 selectively binds to and blocks the activity of the 5-HT6 receptor, which may result in an improvement in cognition and negative and positive symptoms associated with schizophrenia. The 5-HT6 receptor is a subtype of the 5-HT receptor that binds the endogenous neurotransmitter serotonin, and is thought to be involved in the regulation of various cognitive processes.
Clinical Trials
AVN-211 has undergone Phase 2 clinical trials for the treatment of schizophrenia. The trials have shown promising results, with patients demonstrating significant improvements in cognitive function and a reduction in the severity of both positive and negative symptoms.
Related Terms
See Also
External links
- Medical encyclopedia article on AVN-211
- Wikipedia's article - AVN-211
This WikiMD dictionary article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski